Sustainability in Mind – Aptar Pharma’s Way Forward to Circular Solutions

The pharma packaging and drug device industry is constantly evolving to optimise drug delivery, keep up with medical advances and ensure regulatory compliance. Trends like sustainability, cost-efficiency and digitisation continue to shape the sector, and the COVID-19 pandemic remains a challenge.  

Today, there are three marketed nasal vaccines available for human use but many more are in development for both human and veterinary use.Nasal vaccination provides an alternative to the more conventional Injectable drug delivery system. Mucosal immunity can develop via interaction with immune modulators present in the nasal cavity, where the nasal associated lymphoid tissue (NALT) region plays a dominant role

The innovative, easy-to-use connected drug delivery device and companion mobile app will contribute to improving dose compliance and adherence, thus optimizing patient treatment outcomes.

Ophthalmic diseases such as Age-related Macular Degeneration (AMD) and Glaucoma are potentially chronic conditions, requiring life-long medical therapy. Failure by the patient to adhere to a proper treatment regimen may lead to disease progression and visual loss, in addition to all of the consequences around quality of life and capacity to work.

Aptar Pharma’s patented Cartridge Pump System (CPS), was recently reviewed by the U.S. FDA as the drug delivery device in the approval of Oyster Point Pharma’s TYRVAYA™ (varenicline solution) Nasal Spray 0.03 mg, the first and only nasal spray approved for the treatment of the signs and symptoms of dry eye disease.

PureHale Technology Platform

Better Breathing Made Easy

Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, and i2c Pharmaceutical Services, a leading service provider for the development of pharmaceutical formulations, today announced an exclusive partnership to co-develop and promote i2c’s patented pressurized metered dose inhaler (pMDI) technology, Respitab®.

We design, develop and manufacture a comprehensive range of innovative and patient-focused drug delivery systems, services and proven solutions for the widest range of biotechnology, healthcare and pharmaceutical applications.

Aptar announced today that following the entry into exclusive negotiations with Voluntis (ENXTPA: ALVTX) on June 21, 2021, and after completion of the consultation procedure of the employee representative bodies of Voluntis, it has signed on July 22, 2021 a share purchase agreement for the acquisition...

Our specialist analytical, laboratory and regulatory services add value at every stage of the drug development process, accelerating and de-risking your program along the way.

Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announced that they have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital.

Aptar Pharma Brochure

If you’re looking for news, product information and market trends from leading pharma companies, the CPHI-Online.com Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner.

Aptar Pharma Services Brochure

The collaboration will focus on bringing together connected drug delivery devices and the digital platform for asthma and COPD in China and other Asian markets.

Aptar Pharma, Connected Health Brochure

The single-use, ready-to-use, one-step nasal delivery device can deliver a formulation in an emergency situation quickly and easily.

In this article, Christophe Marie, Global Product Sustainability Director, and Taylor Price, Manager, Global Sustainability, both at AptarGroup, and Julien Storz, Director of Business Development, Consumer Healthcare, at Aptar Pharma, chart the commitments and progress made to date by Aptar in achieving its sustainability targets. The authors also provide examples of integrated, circular economy initiatives undertaken by Aptar Pharma at a product solution level and comment on concrete commitments that can be made to further progress towards sustainability.

Acquisition reflects movement of treatments being administered by patients at home rather than by healthcare providers.

In these short interviews, Sai Shankar, Adam Shain and Marcus Bates discuss the full potential of connectivity, coronavirus as a potential accelerator of adoption, and the place of connected drug delivery systems within Aptar Pharma’s broader offering to industry.

AptarGroup, Inc. (NYSE: ATR), a global leader in consumer dispensing, active packaging and drug delivery solutions, announced today that it has acquired Noble International, a leader in drug delivery training devices and patient onboarding.

A review on how the use of propellants in pressurized metered dose inhalers has evolved and how alternative propellants, such as more environmentally friendly propellants, could be a catalyst for greater patient adherence.

The system protects oral solid drug products with a 3-Phase Activ-Polymer solution that is fully integrated into the blister package.

Aptar Pharma thrives on transforming ideas into commercial opportunities, bringing drug delivery solutions to market for customers around the world. Discover how we can help you with your next drug delivery challenge.

Provides migraine sufferers with a convenient, patient-friendly delivery approach.

Discover why Aptar Pharma is the go-to drug delivery expert. Our life-life virtual booth is rich in content, featuring 3D products, multi-media videos, brochures, scientific publications and more for you to experience. Hover your mouse cursor over the colored circle hotspots to uncover and interact with our broad range of complete product and service solutions. Enjoy an enhanced virtual visitor experience, and be sure to book a meeting with one of our Aptar Pharma experts to find out how we can help you solve your next drug delivery challenge. To visit our virtual booth, click the “Download” button

Aptar’s nasal Unidose device - the result of a 10-year customer collaboration - marks the first FDA approval of a prescription drug using the company’s patented Unidose Powder System.

This webinar originally aired as part of CPHI Discover - 17-28 May 2021 Nasal spray drug delivery can provide significant advantages over traditional approaches to vaccine administration. In this session, hear from Aptar Pharma and Vaccine Market Review on nasal physiology and Vaccine targets.  This session will serve as an introduction to Aptar Pharma and Vaccine Market Review nasal physiology and vaccine targets. Discussion points include: Overview of intranasal formulations Review nasal vaccine Opportunities Aptar Pharma device offerings

Aptar Pharma, a leading drug delivery systems provider, will host a live educational webinar reviewing new methodologies in assessing CNS drug deliveries. Taking place on July 17 at 3pm GMT, the webinar, entitled “New Tools to advance CNS Drug Delivery”, will be hosted by Dr. Julie D. Suman, President of Next Breath, an Aptar Pharma business, and Dr. Philip Kuehl, Senior Scientist, Lovelace Biomedical.

This webinar originally aired as part of CPHI Discover - 17-28 May 20211. Drug repurposing has gained traction in the past year amidst the COVID-19 vaccine race - what are the challenges & potential benefits of drug repurposing, compared to the traditional drug development process? What is drug repurposing? Benefits to the development process- speed to market, risk, costs Advantages of nasal delivery and the challenges of repurposing Patient benefits -Our track record and case study Case Study: Repurposing Generic Drugs for COVID-19 and Cancer Using AI-Powered Technology

PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.

There are several key strategic decisions to be made in the rapid development process of COVID-19 vaccines and treatments, including where to target the drug delivery, the appropriate formulation, the correct device and the best regulatory pathway. This webinar discusses these challenges for nasal and pulmonary drug delivery.

PureHale is a new portable drug delivery device designed for upper respiratory care.

The industry’s first cordless, ready-to-use, nebulizer-like system

PureHale™ is a cordless, nebulizer-like device that comes pre-filled and allows users to relieve their symptoms wherever and whenever needed.

Approval expands the regulatory acceptance of Aptar Pharma’s OSD as an approved delivery system for preservative-free eye care formulations.

Aptar Pharma’s Ophthalmic Squeeze Dispenser is the leading device for preservative-free prescription and over-the-counter products. Featuring unrivaled microbiological safety and a proven track record with more than  300 market references worldwide, it is the only FDA-reviewed technology for multidose, preservative-free systems in eye care

When patients self-administer their medications, 60% do not take them as intended and over half of all patients are non-adherent. The resulting cost of non-adherence and non-optimized therapy is steep and everyone pays the price, from Pharmaceutical companies and payers to HCPs and their patients. The cost of non-adherence alone is US$300 billion per year with $188 billion of US pharma revenue lost. Aptar provides a broad range of Digital Healthcare disease management solutions that are ideal for patients who will self-administer their medications. Our technology has the potential to augment patient care, deliver value across the digital health ecosystem and deliver better patient outcomes providing a more seamless engagement for HCPs, payers, and our Pharma partners in a more connected future.This webinar originally aired as part of Pharmapack Europe 2021

Whether it is for new drug development or Vial-to-Prefilled Life Cycle Management projects, choosing the right primary packaging components is essential and will condition the success of the formulation, as well as the manufacturing and commercialization. As PFS components come in direct contact with the drug, it must remain protected throughout its life cycle, while enabling the safe & efficient delivery of the dose, even when integrated in an autoinjector. This session will discuss the key criteria that must be considered when selecting a Pre-Filled Syringe Plunger and Rigid Needle Shield for biologics and sensitive vaccines, as well as services to de-risk projects and optimized time-to-market. The performance of Aptar Pharma solutions will be demonstrated, addressing machinability, drug-container compatibility, container closure integrity under deep-cold conditions, as well as functional performance for facilitating delivery and autoinjector integration.

In this webinar, originally broadcast as part of the Pharmapack Europe show, speaker Christophe Marie, Global Product Sustainability Director, Aptar Pharma discusses how key Pharmaceutical players are acknowledging that caring for human health is closely tied to caring for the health of the planet. However, the nature of the global Pharma business makes this a challenge to accomplish without collaboration from the full value chain.
Aptar Pharma, a key partner to the Pharmaceutical industry, is committed to furthering a more sustainable business. During his Learning Lab presentation Christophe Marie will share how Aptar is addressing the challenges of sustainability and the aspirations, goals and targets that can support a more sustainable pharmaceutical industry.
Additionally, he will outline what pioneering solutions will have the potential to evolve pharmaceutical packaging and support circular economy.
This session was broadcast as part of the Pharmapack show.

In this webinar, originally broadcast as part of the Pharmapack Europe show, speaker Marcus Bates, Vice President, Digital Healthcare, Aptar Pharma covers an introduction to Connected Devices and the different therapeutic areas that they touch. He also reviews the interaction and interoperability between the connected device and the software platform. He discusses the need for clear definition of the intended use and how this will drive the claims which ultimately leads to the regulatory classification. He also reviews the regulatory classification, regulatory hurdles and the importance of building a road map enabling Real World Data generation. Finally, we will discuss the value and ROI for Connected devices, the most advanced countries for regulatory and reimbursement pathways.

In this webinar, speaker Gemma Budd, Director of Business Development, Nanopharm, will highlight the considerations for both systemic/N2B and intranasal vaccines, and the differences in approach when designing the best device and formulation combination. This session was originally broadcast as part of the Pharmapack Europe 2022. Nasal sprays have been around for decades to successfully manage conditions such as allergic rhinitis (hayfever), where treatment of the nasal cavity is the target. Locally acting nasal drug products continue to be developed to treat other infectious diseases, with a big focus on biologic molecules. Furthermore, the COVID-19 pandemic has accelerated the interest in intranasal vaccine administration to enable rapid roll out of vaccines with fewer supply chain challenges for respiratory diseases, and these products target the NALT region of the nose. By contrast, due to the potential for enhanced and rapid bioavailability, there is resurgence of interest in intranasal delivery to treat systemic disease, and particularly CNS indications, where direct nose-to-brain (N2B) delivery via targeting the olfactory region of the nose.

The COVID-19 pandemic brought on a new age of connected health, with telehealth utilization rates spiking 78 times higher than in February 2020. Telehealth utilization has now stabilized and remains 38 times higher than in February 2020. As new biologic drugs are launched onto the market; more patients can receive treatment in their home as opposed to going to a clinic for an IV infusion. For patients receiving care at home vs. in-clinic a significant challenge that must be overcome is proper training.
The presenters of this abstract have developed and launched training devices, Instructions For Use, and instructional videos to provide patients with the necessary training for success. HCPs typically have 15-20 minutes to onboard a patient. Lack of time paired with the nuances and differences of each device make it nearly impossible to provide effective training and onboarding. Patients that do receive training are still faced with the effects of the forgetting curve, where memory retention drops off over time.